Pembrolizumab with radiotherapy and surgery improves survival in high-risk soft tissue sarcoma
1. Pembrolizumab plus radiotherapy and surgery significantly improved disease-free survival. 2. Grade 3 or higher adverse events were more common ...
1. Pembrolizumab plus radiotherapy and surgery significantly improved disease-free survival. 2. Grade 3 or higher adverse events were more common ...
1. Overall response rate to afami-cel in both groups was 37%. 2. The majority of adverse-events were moderate in nature ...
1. 37% of study patients had an objective response to treatment with atezolizumab. 2. Median progression-free survival was 20.8 months. ...
1. Combination therapy with gemcitabine and docetaxel for patients with metastatic or locally advanced synovial sarcoma met the primary endpoint ...
1. The United States regimen had greater event-free survival and less associated febrile neutropenia compared to the European regimen. 2. ...
Click to read this study in JAMA Dermatology.
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.
© 2021 2 Minute Medicine, Inc. - Physician-written medical news.
© 2021 2 Minute Medicine, Inc. - Physician-written medical news.